High dose chemotherapy followed by autologous stem cell transplantation is the treatment of choice for relapsed Hodgkin lymphoma (HL). We analyzed 100 consecutive patients who underwent ASCT at our center between January 1999 and June 2019 for relapsed or refractory disease with a median age of 28 years (range: 9–65). At ASCT, 59 were in complete remission (CR) while 31 achieved partial remission (PR) and 10 had refractory disease (RD). Most had BEAM conditioning with a median infused cell dose of 4.84 × 10⁶ CD 34 cells/kg. Prompt engraftment occurred in 97 patients at a median of 11 days. The day 100 transplant related mortality (TRM) was 5%. At a median of 37 months follow up, 79 patients are alive while 34 have relapsed. The 3-year event free survival (EFS) and overall survival (OS) are 62.3 ± 0.5% and 77.9 ± 4.4% respectively. The 3-year OS for patients in CR, PR and RD were 83.0 ± 5.2%, 78.4 ± 8.1% and 38.9 ± 1.7 respectively [p = 0.007] while the 3-year EFS for CR, PR and RD were 73.1 ± 6.2%, 61.3 ± 9.2% and 25.0 ± 1.5 respectively [p = 0.005]. Only disease status at time of ASCT was found to correlate with both OS and EFS. ASCT for HL is associated with good outcomes and low TRM. Disease status at ASCT impacted both OS and EFS and strategies to improve outcomes in patients with refractory disease needs to be explored.

大剂量化疗后进行自体干细胞移植是复发性霍奇金淋巴瘤 (HL) 的首选治疗方法。我们分析了 1999 年 1 月至 2019 年 6 月期间在我们中心接受 ASCT 的 100 名复发或难治性疾病的连续患者，中位年龄为 28 岁（范围：9-65 岁）。在 ASCT 中，59 人完全缓解（CR），31 人达到部分缓解（PR），10 人患有难治性疾病（RD）。大多数接受了 BEAM 调节，中位注入细胞剂量为 4.84 × 10 ⁶CD 34 个细胞/kg。97 名患者在中位时间为 11 天时迅速植入。第 100 天移植相关死亡率 (TRM) 为 5%。在中位 37 个月的随访中，79 名患者存活，34 名患者复发。3 年无事件生存率 (EFS) 和总生存率 (OS) 分别为 62.3 ± 0.5% 和 77.9 ± 4.4% 。CR、PR 和 RD 患者的 3 年 OS 分别为 83.0 ± 5.2%、78.4 ± 8.1% 和 38.9 ± 1.7 [p = 0.007]，而 CR、PR 和 RD 的 3 年 EFS 为 73.1 ± 6.2  % , 61.3 ± 9.2% 和 25.0 ± 1.5 [ p  = 0.005] 。只有 ASCT 时的疾病状态被发现与 OS 和 EFS 相关。HL 的 ASCT 与良好的结果和低 TRM 相关。ASCT 的疾病状态影响 OS 和 EFS，需要探索改善难治性疾病患者预后的策略。